[go: up one dir, main page]

US20220213020A1 - Synthesis of intermediates for producing prostacyclin derivatives - Google Patents

Synthesis of intermediates for producing prostacyclin derivatives Download PDF

Info

Publication number
US20220213020A1
US20220213020A1 US17/577,222 US202217577222A US2022213020A1 US 20220213020 A1 US20220213020 A1 US 20220213020A1 US 202217577222 A US202217577222 A US 202217577222A US 2022213020 A1 US2022213020 A1 US 2022213020A1
Authority
US
United States
Prior art keywords
compound
formula
batch
synthesis
purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/577,222
Inventor
Hitesh Batra
Sudersan M. TULADHAR
David A. Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Priority to US17/577,222 priority Critical patent/US20220213020A1/en
Publication of US20220213020A1 publication Critical patent/US20220213020A1/en
Priority to US18/886,228 priority patent/US20250002442A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C07C45/81—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/14—Benz[f]indenes; Hydrogenated benz[f]indenes

Definitions

  • the present application generally relates to chemical synthetic methods and in particular, to synthesis of aldehyde compounds, which may be useful in preparation of pharmaceutically active prostacyclins, such as treprostinil.
  • the heating can comprise irradiating the solution with microwave radiation.
  • aryl alone or in combination with another radical, means a carbocyclic aromatic system containing one, two, or three rings wherein such rings may be attached together in a pendent manner or may be fused.
  • aryl embraces aromatic radicals including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indyl, and biphenyl.
  • a substituted aryl group may be optionally substituted at one or more positions with one or more substituents, which may be independently selected from the group consisting of —NO 2 , —CN, halogen (e.g., —F, —Cl, —Br or —I), (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, and halo(C 1 -C 3 )alkoxy.
  • substituents may be independently selected from the group consisting of —NO 2 , —CN, halogen (e.g., —F, —Cl, —Br or —I), (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, and halo(C 1 -C 3 )alkoxy.
  • Prostacyclin derivatives are useful pharmaceutical compounds possessing activities, such as platelet aggregation inhibition, gastric secretion reduction, lesion inhibition, and bronchodilation.
  • Treprostinil the active ingredient in Remodulin®, Tyvaso®, and OrenitramTM
  • Methods of making treprostinil and other prostacyclin derivatives are described, for example, in Moriarty, et al., J. Org. Chem. 2004, 69, 1890-1902, Drug of the Future, 2001, 26(4), 364-374, U.S. Pat. Nos. 6,441,245, 6,528,688, 6,700,025, 6,809,223, 6,756,117, 8,461,393, 8,481,782; 8,242,305, 8,497,393, and 8940930; U.S. Published Patent Application Nos. 2012-0197041, 2013-0211145, 2014-0024856, 2015-0025255; and PCT Publication No. WO2012/009816.
  • Treprostinil also known as UT-15, LRX-15, 15AU81, UNIPROSTTM, BW A15AU;
  • aldehyde compounds can be intermediates in processes for producing treprostinil and other prostacyclin derivatives or pharmaceutically acceptable salts or esters thereof, such as the processes disclosed in Moriarty, et al. J. Org. Chem. 2004, 69, 1890-1902, Drug of the Future, 2001, 26(4), 364-374, U.S. Pat. Nos. 6,441,245, 6,528,688, 6,700,025, 6,809,223, 6,756,117, 7,417,070, 8,461,393, 8,481,782, 8,242,305, and 8,497,393, U.S. Published Patent Application Nos. 2012-0190888 and 2012-0197041, PCT Publication No. WO2012/009816.
  • the present disclosure provides a method of producing a compound of formula 3:
  • the heating comprises irradiating said solution with a microwave radiation.
  • X may be hydrogen, an alkoxy group or OR 2 , where unsubstituted or substituted aryl, or unsubstituted or substituted benzyl.
  • the heating with the microwave radiation may be performed at a temperature ranging from 150° C. to 200° C. or from 175° C. to 195° C., such as within a range of 182-185° C.
  • the heating with the microwave radiation may be performed for 1 hour to 30 hours, from 2 hours to 25 hours, from 2 hours to 20 hours, from 2 hours to 15 hours, from 3 hours to 14 hours, any value or any subrange within these ranges.
  • the reaction times may be significantly lower compared to the ones of prior art methods.
  • solvents include, but are not limited to, 1,2-dichlorobenzene or tetrahydronaphtalene. This means that one of the isomers, e.g. the compound of formula 3 may crystallize, while the other of the isomers, e.g. the compound of formula 3, would remain dissolved in the solvent.
  • the methods described herein allow producing a high-purity batch of the compound of formula 3 having a purity of at least 95% by weight of the composition, at least 96% or at least 97%, at least 98%, at least 98.5%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, least 99.7%, at least 99.8%, or at least 99.9% by weight of the composition.
  • the methods described herein permit production of the compound of formula 3 in large quantities, such as at least 10 g, at least 20 g, at least 30 g, at least 50 g, at least 80 g, at least 100 g, at least 150 g, at least 200 g, at least 250 g, at least 300 g, at least 400 g, at least 500 g, at least 800 g, at least 1000 g, at least 1200 g, at least 1500 g, at least 2000 g, at least 2500 g, at least 3000 g, at least 3500 g, at least 4000 g, at least 4500 g, at least 5000 g, at least 6000 g; at least 7000 g, at least 8000 g, at least 9000 g, or at least 10000 g.
  • X may be hydrogen or an alkoxy group, which may be, for example, C 1 -C 8 alkoxy group or C 1 -C 4 alkoxy group, such as methoxy or ethoxy.
  • the solvent in the solution comprising the compound of formula 2 may comprise, for example, at least one of triglyme, N-methylpyrrolidinone, tetradecane, tetrahydronaphthalene, Dowtherm ATM p-chlorophenol, 1,2-dichlorobenzene, and diphenyl ether.
  • the solvent in the solution comprising the compound of formula 2 may comprise, for example, at least one of 1,2-dichlorobenzene and tetrahydronaphtalene.
  • X may be OR 2 , where R 2 is C 1-4 alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted benzyl.
  • the C 1-4 alkyl can be methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.
  • Non-limiting examples of X include OCH 3 ; OCH 2 CH 3 and OCH 2 Ph.
  • the solvent in the solution comprising the compound of formula 2 may comprise, for example, at least one of triglyme, N-methylpyrrolidinone, tetradecane, tetrahydronaphthalene, Dowtherm ATM (a mixture of 26.5% diphenyl and 73.5% diphenyl oxide), p-chlorophenol, 1,2-dichlorobenzene and diphenyl ether.
  • the solvent in the solution comprising the compound of formula 2 may comprise, for example, at least one of 1,2-dichlorobenzene and tetrahydronaphtalene.
  • the compound of formula 3 may be converted to a compound of formula 5
  • R 1 is selected from (a) benzyl or substituted benzyl and (b) CH 2 COOR 4 , wherein R 4 is C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tent-butyl.
  • R 4 is C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tent-butyl.
  • the purity of a batch of the compound of formula 5 may be as high as purity of the batch of the compound of formula 3.
  • O-alkylation of phenol is known in the art, see e.g. P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc.
  • O-alkylation may be performed by reacting the compound of formula 3 with benzyl halides, such as BnCl, BnBr or BnI. Such reaction may be performed in an alkaline solution, which may be, for example, an aqueous solution of K 2 CO 3 .
  • alkaline solution which may be, for example, an aqueous solution of K 2 CO 3 .
  • Other O-alkylation conditions of phenol are known in the art, see e.g. P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis,” John Wiley & Sons, Inc., 2007, 4 th Edition, page 370.
  • a substituted benzyl group may be optionally substituted at one or more meta, ortho, or para positions with one or more substituents, which may be independently selected from the group consisting of —NO 2 , —CN, halogen (e.g., —F, —Cl, —Br or —I), (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, and halo(C 1 -C 3 )alkoxy.
  • substituents which may be independently selected from the group consisting of —NO 2 , —CN, halogen (e.g., —F, —Cl, —Br or —I), (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, and halo(C 1 -C 3 )alkoxy.
  • the compound of formula 5 may then converted to treprostinil or its pharmaceutically acceptable salt through a process comprising Pauson-Khand cyclization.
  • a process comprising Pauson-Khand cyclization Such processes are disclosed, for example, in U.S. Pat. Nos. 8,481,782, 6,700,025, 6,809,223, 6,441,245, 6,765,117, 6,528,688, and U.S. Published Patent Application Nos. 2012-0190888 and 2012-0197041.
  • the compound of formula 3 may be used for forming a compound of formula 11
  • O-alkylation is known in the art, see e.g. P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc. 2007, 4th edition; page 390; F. Martin and P. J. Garrison; J. Org. Chem., 1982, 47, 1513; T. Satoh, M. Ikeda, M. Miura and M. Nomura: J. Org. Chem., 1997, 62, 4877. Hydrolysis of esters is known in the art as well.
  • the selective hydrolysis may be performed using a bulky base, such as barium hydroxide, cesium hydroxide, or trialkyl ammonium hydroxide.
  • the trialkyl ammonium hydroxide can be tributyl ammonium hydroxide or trimethyl ammonium hydroxide.
  • a base for selective hydrolysis may be an alkali metal hydroxide.
  • a base used in selective hydrolysis may selectively hydrolyze one (less hindered) isomer, and this may provide the advantage of separating the desired isomer in the present synthesis, see e.g. Scheme 2.
  • Ester hydrolysis using various conditions are disclosed, for example, in P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc. 2007, 4th edition; page 543-544.
  • a phenolic protecting group is a modification that protects the hydroxyl group from participating in reactions that are occurring in other parts of the molecule. Suitable phenolic protecting groups are well known to those of ordinary skill in the art and include those found in P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc. 2007, 4th edition; page 367-430, the entire teachings of which are incorporated herein by reference.
  • Exemplary phenolic protecting groups include, but are not limited to, actetyl, benzoyl, benzyl, p-methoxyethoxymethyl, methoxymethyl, dimethoxytrityl, p-methoxybenzyl, trityl, silyl (e.g., trimethylsilyl (TMS), tert-butyldimethylsilyl (TBMDS), tert-butyldimethylsilyloxymethyl (TOM) or triisopropylsilyl (TIPS), tetrahydropyranyl (THP), methyl and ethoxyethyl (EE).
  • TMS trimethylsilyl
  • TBMDS tert-butyldimethylsilyl
  • TOM tert-butyldimethylsilyloxymethyl
  • TIPS triisopropylsilyl
  • TIPS tetrahydropyranyl
  • EE methyl and ethoxyethy
  • the compound of formula 11 may then converted to treprostinil or its pharmaceutically acceptable salt through a process comprising Pauson-Khand cyclization.
  • a process comprising Pauson-Khand cyclization.
  • Such processes are disclosed, for example, in U.S. Pat. Nos. 8,481,782, 6,700,025, 6,809,223, 6,441,245, 6,765,117, and 6,528,688 and U.S. Published Patent Application Nos. 2012-0190888 and 2012-0197041.
  • the compound of formula 2 used for making the compound of formula 3 may be produced by allylating a compound of formula 1
  • the disclosed methods may provide one or more of the following advantages: a) reduce reaction times; b) provide high purity batches of a desired isomer by using selective crystallization of the desired isomer depending on the solvents used; c) eliminate column chromatographic purifications and thereby, significantly save manpower and large volume of solvents; d) be scaled up to kilo-gram quantities; e) the compound of formula 3 may be used to synthesize various O-ethers, esters and acid functionalities, which may be useful synthons for the synthesis of prostacyclins, such as treprostinil.
  • Embodiments described herein are further illustrated by, though in no way limited to, the following examples.
  • a protocol (Scheme 1) has been developed for the synthesis of 2-allyl-3-hydroxy benzaldehyde (3) via Claisen rearrangement of allyl-ether of 3-hydroxybenzaldehyde (2) using microwave.
  • the allyl ether (2) is heated by irradiating microwaves in various solvents (see Table 1) app. at 180° C. for 7-12 hrs.
  • the use of microwave enhances the rate of reaction and significantly may reduce the reaction times over conventional thermal rearrangement.
  • the desired isomer (3) crashes out as white to off-white solid leaving the non-desired aldehyde (regio-isomer) (4) in mother liquor.
  • allylether (7) (308 g) and tetrahydronaphthalene (300 mL).
  • This reaction mixture was heated slowly up to 180-182° C. (ramped the temp. in 5-10 minutes, internal temperature) in a microwave (power: 1500 Watts) and was kept at this temperature while stirring for 7-8 h.
  • the reaction mixture turned brown and the reaction mixture was cooled to room temperature followed by cooling at 0 to 5° C. for 30 minutes.
  • the solid was filtered and dried to obtain off-white solid (3-hydroxy-2-allylbenzaldehyde, 8) 145.5 g (47%).
  • the compound (8) was characterized by spectral data. Completion of reaction was monitored by TLC using a thin layer silica gel plate; eluent: 15% ethyl acetate in hexanes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil.

Description

    RELATED APPLICATIONS
  • The present application is a Continuation of U.S. application Ser. No. 16/264,053, filed Jan. 31, 2019, which is a Continuation of U.S. application Ser. No. 15/439,189, filed Feb. 22, 2017, which is a Continuation of U.S. application Ser. No. 14/887,298, filed Oct. 19, 2015, which claims priority to U.S. provisional application no. 62/066,009 filed Oct. 20, 2014, which is incorporated herein by reference in its entirety.
    • FIELD
  • The present application generally relates to chemical synthetic methods and in particular, to synthesis of aldehyde compounds, which may be useful in preparation of pharmaceutically active prostacyclins, such as treprostinil.
    • SUMMARY
  • A method of producing a compound of formula 3:
  • Figure US20220213020A1-20220707-C00001
  • comprising heating a solution comprising a compound of formula 2:
  • Figure US20220213020A1-20220707-C00002
  • and an organic solvent, and wherein X is hydrogen, an alkoxy group or OR2, wherein R2 is unsubstituted or substituted aryl, or unsubstituted or substituted benzyl. The heating can comprise irradiating the solution with microwave radiation.
    • DETAILED DESCRIPTION
  • Unless otherwise specified, “a” or “an” means “one or more.”
  • The term “aryl,” alone or in combination with another radical, means a carbocyclic aromatic system containing one, two, or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term “aryl” embraces aromatic radicals including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indyl, and biphenyl. A substituted aryl group may be optionally substituted at one or more positions with one or more substituents, which may be independently selected from the group consisting of —NO2, —CN, halogen (e.g., —F, —Cl, —Br or —I), (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy, and halo(C1-C3)alkoxy.
  • Prostacyclin derivatives are useful pharmaceutical compounds possessing activities, such as platelet aggregation inhibition, gastric secretion reduction, lesion inhibition, and bronchodilation.
  • Treprostinil, the active ingredient in Remodulin®, Tyvaso®, and Orenitram™, was first described in U.S. Pat. No. 4,306,075. Methods of making treprostinil and other prostacyclin derivatives are described, for example, in Moriarty, et al., J. Org. Chem. 2004, 69, 1890-1902, Drug of the Future, 2001, 26(4), 364-374, U.S. Pat. Nos. 6,441,245, 6,528,688, 6,700,025, 6,809,223, 6,756,117, 8,461,393, 8,481,782; 8,242,305, 8,497,393, and 8940930; U.S. Published Patent Application Nos. 2012-0197041, 2013-0211145, 2014-0024856, 2015-0025255; and PCT Publication No. WO2012/009816.
  • Various uses and/ or various forms of treprostinil are disclosed, for examples, in U.S. Pat. Nos. 5,153,222, 5,234,953, 6,521,212, 6,756,033, 6,803,386, 7,199,157, 6,054,486, 7,417,070, 7,384,978, 7,879,909, 8,563,614, 8,252,839, 8,536,363, 8,410,169, 8,232,316, 8,609,728, 8,350,079, 8,349,892, 7,999,007, 8,658,694, 8,653,137, 9,029,607, 8,765,813, 9,050,311, U.S. Published Patent Application Nos. 2009-0036465, 2008-0200449, 2010-0076083, 2012-0216801, 2008-0280986, 2009-0124697, 2014-0275616, 2014-0275262, 2013-0184295, 2014-0323567, PCT Publication No. WO00/57701.
  • Treprostinil, also known as UT-15, LRX-15, 15AU81, UNIPROST™, BW A15AU;
  • Figure US20220213020A1-20220707-C00003
  • and U-62,840 has the following chemical formula:
  • The present inventors developed novel methods for synthesizing aldehyde compounds. These aldehyde compounds can be intermediates in processes for producing treprostinil and other prostacyclin derivatives or pharmaceutically acceptable salts or esters thereof, such as the processes disclosed in Moriarty, et al. J. Org. Chem. 2004, 69, 1890-1902, Drug of the Future, 2001, 26(4), 364-374, U.S. Pat. Nos. 6,441,245, 6,528,688, 6,700,025, 6,809,223, 6,756,117, 7,417,070, 8,461,393, 8,481,782, 8,242,305, and 8,497,393, U.S. Published Patent Application Nos. 2012-0190888 and 2012-0197041, PCT Publication No. WO2012/009816.
  • In one embodiment, the present disclosure provides a method of producing a compound of formula 3:
  • Figure US20220213020A1-20220707-C00004
  • by heating a solution comprising a compound of formula 2
  • Figure US20220213020A1-20220707-C00005
  • and an organic solvent. In some embodiments, the heating comprises irradiating said solution with a microwave radiation. In the above formulae, X may be hydrogen, an alkoxy group or OR2, where unsubstituted or substituted aryl, or unsubstituted or substituted benzyl.
  • Use of microwave radiation in chemistry is known to those skilled in the art. See e.g. Polshettiwar, V.; et al Accounts of Chemical Research 2008, 41 (5), 629-639; Bowman, M. D.; Organic Process Research & Development 2007, 12 (1), 41-57; Sauks, J. M. et al., Organic Process Research & Development 2014, 18(11):1310-1314; Microwaves in organic synthesis, Andre Loupy (ed), Wiley-VCH, Weinheim, 2006; Microwaves in organic synthesis. Thermal and non-thermal microwave effects, Antonio de la Hoz, Angel Diaz-Ortiz, Andres Moreno, Chem. Soc. Rev., 2005, 164-178; Developments in Microwave-assisted Organic Chemistry. C. Strauss, R. Trainor. Aust. J. Chem., 48 1665 (1995); Microwaves in Organic and Medicinal Chemistry, 2nd, Completely Revised and Enlarged Edition, Wiley-VCH, Weinheim, 2012.
  • In certain embodiments, the heating with the microwave radiation may be performed at a temperature ranging from 150° C. to 200° C. or from 175° C. to 195° C., such as within a range of 182-185° C.
  • The heating with the microwave radiation may performed for 1 hour to 30 hours, from 2 hours to 25 hours, from 2 hours to 20 hours, from 2 hours to 15 hours, from 3 hours to 14 hours, any value or any subrange within these ranges. In some embodiments, the reaction times may be significantly lower compared to the ones of prior art methods.
  • Use of microwave radiation or conventional heating to heat a solution comprising the compound of formula 2 may result in producing the isomer of the compound of formula 3, a compound of formula 4
  • Figure US20220213020A1-20220707-C00006
  • Selection of appropriate solvents can result in separating the compound of formula 3 from the compound of formula 4 through a selective crystallization of one of the isomers. Appropriate solvents include, but are not limited to, 1,2-dichlorobenzene or tetrahydronaphtalene. This means that one of the isomers, e.g. the compound of formula 3 may crystallize, while the other of the isomers, e.g. the compound of formula 3, would remain dissolved in the solvent. In some embodiments, the methods described herein allow producing a high-purity batch of the compound of formula 3 having a purity of at least 95% by weight of the composition, at least 96% or at least 97%, at least 98%, at least 98.5%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, least 99.7%, at least 99.8%, or at least 99.9% by weight of the composition.
  • Selective crystallization allows for production high-purity batches of the compound of formula 3 without performing column chromatography purifications, which may save manpower, large volumes of solvents, and lost product.
  • In some embodiments, the methods described herein permit production of the compound of formula 3 in large quantities, such as at least 10 g, at least 20 g, at least 30 g, at least 50 g, at least 80 g, at least 100 g, at least 150 g, at least 200 g, at least 250 g, at least 300 g, at least 400 g, at least 500 g, at least 800 g, at least 1000 g, at least 1200 g, at least 1500 g, at least 2000 g, at least 2500 g, at least 3000 g, at least 3500 g, at least 4000 g, at least 4500 g, at least 5000 g, at least 6000 g; at least 7000 g, at least 8000 g, at least 9000 g, or at least 10000 g.
  • In some embodiments, X may be hydrogen or an alkoxy group, which may be, for example, C1-C8 alkoxy group or C1-C4 alkoxy group, such as methoxy or ethoxy. The solvent in the solution comprising the compound of formula 2 may comprise, for example, at least one of triglyme, N-methylpyrrolidinone, tetradecane, tetrahydronaphthalene, Dowtherm A™ p-chlorophenol, 1,2-dichlorobenzene, and diphenyl ether. In some embodiments, the solvent in the solution comprising the compound of formula 2 may comprise, for example, at least one of 1,2-dichlorobenzene and tetrahydronaphtalene.
  • In some embodiments, X may be OR2, where R2 is C1-4 alkyl, unsubstituted or substituted aryl, or unsubstituted or substituted benzyl. The C1-4 alkyl can be methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl. Non-limiting examples of X include OCH3; OCH2CH3 and OCH2Ph. The solvent in the solution comprising the compound of formula 2 may comprise, for example, at least one of triglyme, N-methylpyrrolidinone, tetradecane, tetrahydronaphthalene, Dowtherm A™ (a mixture of 26.5% diphenyl and 73.5% diphenyl oxide), p-chlorophenol, 1,2-dichlorobenzene and diphenyl ether. In some embodiments, the solvent in the solution comprising the compound of formula 2 may comprise, for example, at least one of 1,2-dichlorobenzene and tetrahydronaphtalene.
  • In some embodiments, the compound of formula 3 may be converted to a compound of formula 5
  • Figure US20220213020A1-20220707-C00007
  • using O-alkylation, wherein R1 is selected from (a) benzyl or substituted benzyl and (b) CH2COOR4, wherein R4 is C1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tent-butyl. The purity of a batch of the compound of formula 5 may be as high as purity of the batch of the compound of formula 3. O-alkylation of phenol is known in the art, see e.g. P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc. 2007, 4th edition; page 390; F. Martin and P.J. Garrison; J. Org. Chem., 1982, 47, 1513; T. Satoh, M. Ikeda, M. Miura and M. Nomura: J. Org. Chem., 1997, 62, 4877.
  • In some embodiments, when R1 is hydrogen, O-alkylation may be performed by reacting the compound of formula 3 with benzyl halides, such as BnCl, BnBr or BnI. Such reaction may be performed in an alkaline solution, which may be, for example, an aqueous solution of K2CO3. Other O-alkylation conditions of phenol are known in the art, see e.g. P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis,” John Wiley & Sons, Inc., 2007, 4th Edition, page 370.
  • A substituted benzyl group may be optionally substituted at one or more meta, ortho, or para positions with one or more substituents, which may be independently selected from the group consisting of —NO2, —CN, halogen (e.g., —F, —Cl, —Br or —I), (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy, and halo(C1-C3)alkoxy.
  • In some embodiments, the compound of formula 5 may then converted to treprostinil or its pharmaceutically acceptable salt through a process comprising Pauson-Khand cyclization. Such processes are disclosed, for example, in U.S. Pat. Nos. 8,481,782, 6,700,025, 6,809,223, 6,441,245, 6,765,117, 6,528,688, and U.S. Published Patent Application Nos. 2012-0190888 and 2012-0197041.
  • In some embodiments, when X is OR2, where R2 is C1-4 alkyl, the compound of formula 3 may be used for forming a compound of formula 11
  • Figure US20220213020A1-20220707-C00008
  • through O-alkylation and hydrolysis, wherein R3 is C1-4 alkyl or a phenolic protecting group. O-alkylation is known in the art, see e.g. P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc. 2007, 4th edition; page 390; F. Martin and P. J. Garrison; J. Org. Chem., 1982, 47, 1513; T. Satoh, M. Ikeda, M. Miura and M. Nomura: J. Org. Chem., 1997, 62, 4877. Hydrolysis of esters is known in the art as well. In some embodiments, the selective hydrolysis may be performed using a bulky base, such as barium hydroxide, cesium hydroxide, or trialkyl ammonium hydroxide. In some embodiments, the trialkyl ammonium hydroxide can be tributyl ammonium hydroxide or trimethyl ammonium hydroxide. In some embodiments, a base for selective hydrolysis may be an alkali metal hydroxide. Although the use of bulky bases, such as barium hydroxide and cesium hydroxide, other alkali metal hydroxides, such as potasium hydroxide and sodium hydroxide may be used if they can provide selective hydrolysis of one of regioisomers. A base used in selective hydrolysis may selectively hydrolyze one (less hindered) isomer, and this may provide the advantage of separating the desired isomer in the present synthesis, see e.g. Scheme 2. Ester hydrolysis using various conditions are disclosed, for example, in P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc. 2007, 4th edition; page 543-544.
  • As used herein, “a phenolic protecting group” is a modification that protects the hydroxyl group from participating in reactions that are occurring in other parts of the molecule. Suitable phenolic protecting groups are well known to those of ordinary skill in the art and include those found in P. G. M. Wuts and T. W. Greene, “Greene's Protecting Groups in Organic Synthesis”, John Wiley & Sons, Inc. 2007, 4th edition; page 367-430, the entire teachings of which are incorporated herein by reference. Exemplary phenolic protecting groups include, but are not limited to, actetyl, benzoyl, benzyl, p-methoxyethoxymethyl, methoxymethyl, dimethoxytrityl, p-methoxybenzyl, trityl, silyl (e.g., trimethylsilyl (TMS), tert-butyldimethylsilyl (TBMDS), tert-butyldimethylsilyloxymethyl (TOM) or triisopropylsilyl (TIPS), tetrahydropyranyl (THP), methyl and ethoxyethyl (EE).
  • In some embodiments, the compound of formula 11 may then converted to treprostinil or its pharmaceutically acceptable salt through a process comprising Pauson-Khand cyclization. Such processes are disclosed, for example, in U.S. Pat. Nos. 8,481,782, 6,700,025, 6,809,223, 6,441,245, 6,765,117, and 6,528,688 and U.S. Published Patent Application Nos. 2012-0190888 and 2012-0197041.
  • In some embodiments, the compound of formula 2 used for making the compound of formula 3 may be produced by allylating a compound of formula 1
  • Figure US20220213020A1-20220707-C00009
  • Allylation reactions are disclosed, for example, in By Nicolaou, K. C. et. al.; From Chemistry—A European Journal, 7(17), 3798-3823; 2001; Moriarty R. M. et. al. ; From PCT Int. Appl., 2002053517, 11 Jul, 2002; Mmutlane, Edwin M. et. al. From Organic & Biomolecular Chemistry, 2(17), 2461-2470; 2004; Paul, Caroline E. et. al.; From Chemical Communications (Cambridge, United Kingdom), 48(27), 3303-3305; 2012. In some embodiments, the disclosed methods may provide one or more of the following advantages: a) reduce reaction times; b) provide high purity batches of a desired isomer by using selective crystallization of the desired isomer depending on the solvents used; c) eliminate column chromatographic purifications and thereby, significantly save manpower and large volume of solvents; d) be scaled up to kilo-gram quantities; e) the compound of formula 3 may be used to synthesize various O-ethers, esters and acid functionalities, which may be useful synthons for the synthesis of prostacyclins, such as treprostinil. Embodiments described herein are further illustrated by, though in no way limited to, the following examples.
    • EXAMPLES
  • A protocol (Scheme 1) has been developed for the synthesis of 2-allyl-3-hydroxy benzaldehyde (3) via Claisen rearrangement of allyl-ether of 3-hydroxybenzaldehyde (2) using microwave. The allyl ether (2) is heated by irradiating microwaves in various solvents (see Table 1) app. at 180° C. for 7-12 hrs. The use of microwave enhances the rate of reaction and significantly may reduce the reaction times over conventional thermal rearrangement. Also, the desired isomer (3) crashes out as white to off-white solid leaving the non-desired aldehyde (regio-isomer) (4) in mother liquor.
  • Figure US20220213020A1-20220707-C00010
  • Another methodology developed (Scheme 2) involves the use of methyl 2-allyloxybenzoate (8) for obtaining the Claisen rearranged product methyl 2-allyl-3-hydroxybenzoate (9). During the rearrangement mixture of regio-isomers are produced in app. 3:1 or 2:1 ratio and separation can be challenging. As one can visualize, ester 9 is sterically hindered as compared to ester 10 due to the presence of allyl group at the ortho position and hence is less susceptible to attack by a base for hydrolysis. The inventors took advantage of this steric hinderance available in the molecule and selectively hydrolyzed the regio-isomer 10 to acid and this was subsequently separated by acid-base work-up to obtain pure 2-allyl-3-hydroxybenzoate (9). This is an important intermediate as this can be used to obtain aldehyde (5) by reducing with various chemical reagents such as lithium aluminum hydride (LAH), diisobutyl lithium aluminum hydride (DIBAL) etc.
  • Figure US20220213020A1-20220707-C00011
  • A brief overview of the experiments carried on Claisen rearrangement is given below in table 1.
  • TABLE 1
    Study Results on Claisen Rearrangement (2→3)
    Figure US20220213020A1-20220707-C00012
    Figure US20220213020A1-20220707-C00013
    S.No. Lot # Solvent Amount Temp. Time
    1 D- Triglyme 1.0 g 180-182° 22 h
    1057- C.
    087
    2 D- N-methyl 1.0 g 180-182° 22 h
    1057- pyrrolidinone C.
    088
    3 D- Carbitol 1.0 g 180-182° 19 h
    1057- C.
    089
    4 D- Tetradecane 1.0 g 190-192° 19 h
    1057- C.
    090
    5 D- Tetrahydro- 3.0 g 180-182° 11 h
    1057- naphthalene C.
    063
    6 D- Dowtherm A ™ 1.0 g 190-192°  6 h
    1057- (mixture of C.
    066 diphenyl 26.5%
    and diphenyl
    oxide 73.5%)
    7 D- Neat 4.0  180-182° 30
    1057- 15.0 g  C. min.
    064
    D-
    1057-
    069
    8 D- Para- 1.0 g 160-162°  1 h
    1057- cholorophenol C.
    144
    9 D- N-methyl 1.0 g 180-182°  1 h
    1057- pyrrolidinone C.
    145
    10 D- Tetrahydro 1.0 g 182-185° 11 h
    1057- naphthalene C.
    147
    11 D- 1,2- 1.0 g 175-178° 24 h
    1057- Dichlorobenzene C.
    148
    12 D- 1,2-   5 g 182-185°  7 h
    1057- Dichlorobenzene C.
    153 Microwave
    13 D- Tetrahydro-  50 g 182-185°  4 h
    1057- naphthalene C.
    155 Microwave
    14 D- Tetrahydro- 308 g  182-185° ~7 h
    1057- naphthalene C.
    172 Microwave
    • General Experimental
  • Figure US20220213020A1-20220707-C00014
    • Synthesis of 3-Hydroxy-2-allylbenzaldehyde (8): Bill of Materials
  • Name MW Amount Mole
    Allyl ether (7) NA 308 g NA
    Tetrahydronaphthalene NA 300 mL NA
  • To a 3000 ml one neck, round bottom flask equipped with a condenser and thermometer was added allylether (7) (308 g) and tetrahydronaphthalene (300 mL). This reaction mixture was heated slowly up to 180-182° C. (ramped the temp. in 5-10 minutes, internal temperature) in a microwave (power: 1500 Watts) and was kept at this temperature while stirring for 7-8 h. At this stage the reaction mixture turned brown and the reaction mixture was cooled to room temperature followed by cooling at 0 to 5° C. for 30 minutes. The solid was filtered and dried to obtain off-white solid (3-hydroxy-2-allylbenzaldehyde, 8) 145.5 g (47%). The compound (8) was characterized by spectral data. Completion of reaction was monitored by TLC using a thin layer silica gel plate; eluent: 15% ethyl acetate in hexanes.
    • Synthesis of 2-Allyl-3-benzyloxybenzaldehyde (1):
  • A 500-mL round-bottom flask equipped with a magnetic stirrer and stir bar was charged with a solution of 3-hydroxy-2-allyl benzaldehyde (8) (25 g in 250 mL acetone), benzyl bromide (28.36 g, 1.05 eq.) and potassium carbonate (54.4 g, 2.5 eq.). The mixture was stirred at room temperature overnight (progress of reaction was monitored by TLC). The suspension was filtered and the filtrate was evaporated in vacuo to afford a crude semi-solid mass. This was taken in 550 ml of hexanes and stirred for 2 h. The solid was crashed out of hexanes and filtered to obtain 2-allyl-3-benzyloxybenzaldehyde (1), yield 36.6 g (95%). The compound was confirmed by spectral data. Completion of reaction was monitored by TLC using a thin layer silica gel plate; eluent: 20% ethyl acetate in hexanes.
  • Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention. All of the publications, patent applications and patents cited in this specification are incorporated herein by reference in their entirety.

Claims (9)

1-19. (canceled)
20. A batch for a pharmaceutical manufacturing method comprising at least 10 g of a compound of formula 3:
Figure US20220213020A1-20220707-C00015
wherein X is hydrogen, an alkoxy group or OR.sup.2, wherein R.sup.2 is unsubstituted or substituted aryl, or unsubstituted or substituted benzyl; wherein purity of the compound of formula 3 is at least 96% by weight of the batch.
21. The batch of claim 20, which is produced without column chromatography.
22. The batch of claim 20, wherein the purity of the compound of formula 3 is at least 97% by weight of the batch.
23. The batch of claim 20, wherein the purity of the compound of formula 3 is at least 98% by weight of the batch.
24. The batch of claim 20, wherein the purity of the compound of formula 3 is at least 99% by weight of the batch.
25. The batch of claim 20, comprising at least 100 g of a compound of formula 3.
26. The batch of claim 20, comprising at least 200 g of a compound of formula 3.
27. The batch of claim 20, comprising at least 300 g of a compound of formula 3.
US17/577,222 2014-10-20 2022-01-17 Synthesis of intermediates for producing prostacyclin derivatives Abandoned US20220213020A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/577,222 US20220213020A1 (en) 2014-10-20 2022-01-17 Synthesis of intermediates for producing prostacyclin derivatives
US18/886,228 US20250002442A1 (en) 2014-10-20 2024-09-16 Synthesis of intermediates for producing prostacyclin derivatives

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462066009P 2014-10-20 2014-10-20
US14/887,298 US9593061B2 (en) 2014-10-20 2015-10-19 Synthesis of intermediates for producing prostacyclin derivatives
US15/439,189 US10196342B2 (en) 2014-10-20 2017-02-22 Synthesis of intermediates for producing prostacyclin derivatives
US16/264,053 US10774027B2 (en) 2014-10-20 2019-01-31 Synthesis of intermediates for producing prostacyclin derivatives
US16/991,460 US11225452B2 (en) 2014-10-20 2020-08-12 Synthesis of intermediates for producing prostacyclin derivatives
US17/577,222 US20220213020A1 (en) 2014-10-20 2022-01-17 Synthesis of intermediates for producing prostacyclin derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/991,460 Division US11225452B2 (en) 2014-10-20 2020-08-12 Synthesis of intermediates for producing prostacyclin derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/886,228 Continuation US20250002442A1 (en) 2014-10-20 2024-09-16 Synthesis of intermediates for producing prostacyclin derivatives

Publications (1)

Publication Number Publication Date
US20220213020A1 true US20220213020A1 (en) 2022-07-07

Family

ID=54361211

Family Applications (6)

Application Number Title Priority Date Filing Date
US14/887,298 Active US9593061B2 (en) 2014-10-20 2015-10-19 Synthesis of intermediates for producing prostacyclin derivatives
US15/439,189 Active US10196342B2 (en) 2014-10-20 2017-02-22 Synthesis of intermediates for producing prostacyclin derivatives
US16/264,053 Active US10774027B2 (en) 2014-10-20 2019-01-31 Synthesis of intermediates for producing prostacyclin derivatives
US16/991,460 Active US11225452B2 (en) 2014-10-20 2020-08-12 Synthesis of intermediates for producing prostacyclin derivatives
US17/577,222 Abandoned US20220213020A1 (en) 2014-10-20 2022-01-17 Synthesis of intermediates for producing prostacyclin derivatives
US18/886,228 Pending US20250002442A1 (en) 2014-10-20 2024-09-16 Synthesis of intermediates for producing prostacyclin derivatives

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US14/887,298 Active US9593061B2 (en) 2014-10-20 2015-10-19 Synthesis of intermediates for producing prostacyclin derivatives
US15/439,189 Active US10196342B2 (en) 2014-10-20 2017-02-22 Synthesis of intermediates for producing prostacyclin derivatives
US16/264,053 Active US10774027B2 (en) 2014-10-20 2019-01-31 Synthesis of intermediates for producing prostacyclin derivatives
US16/991,460 Active US11225452B2 (en) 2014-10-20 2020-08-12 Synthesis of intermediates for producing prostacyclin derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/886,228 Pending US20250002442A1 (en) 2014-10-20 2024-09-16 Synthesis of intermediates for producing prostacyclin derivatives

Country Status (8)

Country Link
US (6) US9593061B2 (en)
EP (1) EP3209415B1 (en)
JP (1) JP6224872B1 (en)
KR (1) KR101890080B1 (en)
CN (1) CN107108427A (en)
CA (1) CA2964804C (en)
ES (1) ES2778274T3 (en)
WO (1) WO2016064764A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3060041T1 (en) 2013-10-25 2021-04-30 Insmed Incorporated Prostacyclin compounds
US9593061B2 (en) * 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
DE102016218095A1 (en) 2016-09-21 2018-03-22 Continental Teves Ag & Co. Ohg Electrohydraulic motor vehicle control unit
CN110678174A (en) 2016-09-26 2020-01-10 联合治疗学有限公司 Prodrugs of treprostinil
AU2020265576A1 (en) 2019-04-29 2021-11-25 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
US11634443B2 (en) 2019-08-23 2023-04-25 United Therapeutics Corporation Treprostinil prodrugs
WO2021211916A1 (en) 2020-04-17 2021-10-21 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
AU2021289336A1 (en) 2020-06-09 2023-01-05 Mannkind Corporation Fumaryl diketopiperidine prodrugs of treprostinil
US11826328B2 (en) 2020-12-14 2023-11-28 United Therapeutics Corporation Stable treprostinil prodrugs
CN117479946A (en) 2021-03-03 2024-01-30 联合治疗公司 Dry powder compositions containing treprostinil and its prodrug and further comprising (E) -3,6-bis [4- (N-carbonyl-2-propenyl) amide butyl ] -2,5-diketopiperazine (FDKP)
IL314791A (en) 2022-02-08 2024-10-01 United Therapeutics Corp Combined treatment with terprostinil and iloprost
US20240287105A1 (en) 2023-01-19 2024-08-29 United Therapeutics Corporation Treprostinil analogs and related methods of making and using

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053517A2 (en) * 2001-01-05 2002-07-11 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2811950A1 (en) 1978-03-18 1979-12-13 Hoechst Ag NEW PROSTACYCLIN ANALOGS
JPS56122328A (en) 1980-02-29 1981-09-25 Sumitomo Chem Co Ltd Crystalline amine salt of methanoplastocyclin, its preparation and purifying method
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4306076A (en) 1980-04-23 1981-12-15 The Upjohn Company Inter-phenylene CBA compounds
US4463183A (en) 1980-12-15 1984-07-31 E. R. Squibb & Sons, Inc. Method for preparing a prostacyclin intermediate
US4434164A (en) 1981-06-01 1984-02-28 Pfizer Inc. Crystalline benzothiazine dioxide salts
US4424376A (en) 1981-09-24 1984-01-03 E. R. Squibb & Sons, Inc. Prostacyclin intermediates
US4486598A (en) 1982-02-22 1984-12-04 The Upjohn Company Carbacyclin analogs
JPS5944340A (en) 1982-09-08 1984-03-12 Sankyo Co Ltd Optical active crystalline amine salt of methanoprostacyclin derivative and its preparation
US4561604A (en) 1983-07-18 1985-12-31 Shimano Industrial Company Limited Spinning reel
US4683330A (en) 1984-03-08 1987-07-28 The Upjohn Company Interphenylene carbacyclin derivatives
US4668814A (en) 1984-03-08 1987-05-26 The Upjohn Company Interphenylene carbacyclin derivatives
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
EP0175450B1 (en) 1984-07-18 1989-03-22 The Upjohn Company An interphenylene-carbacyclin compound
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
US5039814A (en) 1990-05-02 1991-08-13 Merck & Co., Inc. Ortho-lithiation process for the synthesis of 2-substituted 1-(tetrazol-5-yl)benzenes
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
CA2056039A1 (en) 1991-01-22 1992-07-23 Philip L. Fuchs Carbacyclin analogs
DE4104606C1 (en) 1991-02-12 1992-10-15 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
DE4202665A1 (en) 1992-01-28 1993-07-29 Schering Ag PROSTACYCLIN AND CARBACYCLINE DERIVATIVES AS A MEDIUM FOR TREATING MULTIPLE Sclerosis
JP4863534B2 (en) 1996-10-25 2012-01-25 スパーナス ファーマシューティカルズ インコーポレイテッド Soluble form osmotic dose delivery system
DE19708496A1 (en) 1997-03-03 1998-09-10 Hoechst Ag Process for enanthanum-pure anthracylin synthesis
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
WO1999021830A1 (en) 1997-10-24 1999-05-06 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
CN1142781C (en) 1997-11-14 2004-03-24 联合治疗公司 Use of 9-deoxy-2', 9-alpha-methano-3-oxa-4,5,6-trinor-3, 7-(1,'3'-interphenylene)-13, 14-dihydro-prostaglandin F, to treat peripheral vascular disease
US20010038855A1 (en) 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
EP1164846A1 (en) 1999-03-31 2002-01-02 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6933385B2 (en) 2001-08-03 2005-08-23 Schering Ag Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use
US6569894B1 (en) * 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
WO2003047584A1 (en) * 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US6756117B1 (en) 2002-12-20 2004-06-29 The United States Of America As Represented By The United States Department Of Energy Photonic polymer-blend structures and method for making
US20060217574A1 (en) * 2003-04-03 2006-09-28 Hirotaka Enokida Method for producing 3,3 diallyl-4,4 dihydroxydiphenylsulfone
CA2736406C (en) 2003-05-22 2014-11-18 United Therapeutics Corporation Compositions comprising diethanolamine salts of trepostinil in the treatment of pulmonary hypertension and other cardiovascular diseases
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
CA2549724C (en) 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
ATE441418T1 (en) 2003-12-16 2009-09-15 United Therapeutics Corp USE OF TREPROSTINIL TO IMPROVE KIDNEY FUNCTION
CN101287457B (en) 2004-04-12 2011-11-16 联合治疗公司 Use of treprostinil to treat neuropathic diabetic foot ulcers
US20080200449A1 (en) 2006-05-15 2008-08-21 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
KR20090117781A (en) 2007-02-09 2009-11-12 유나이티드 세러퓨틱스 코오포레이션 Treprostinil Therapy for Interstitial Lung Disease and Asthma
WO2008100977A2 (en) 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
EP2711024B1 (en) 2007-09-07 2019-03-06 United Therapeutics Corporation Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
JP5851691B2 (en) 2007-12-17 2016-02-03 ユナイテッド セラピューティクス コーポレーション Improved process for producing treprostinil, an active ingredient of remodulin
RS53684B9 (en) 2008-03-18 2019-07-31 Arena Pharm Inc Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
EP2300408B1 (en) 2008-05-08 2016-04-13 United Therapeutics Corporation Process for the preparation of treprostinil monohydrate and its use for storage and shipping
EP2427054A4 (en) 2009-05-07 2014-01-15 United Therapeutics Corp Solid formulations of prostacyclin analogs
CN101891596B (en) 2009-05-22 2013-12-11 上海天伟生物制药有限公司 New compound and preparation method and application thereof
CN101891715B (en) 2009-05-22 2015-09-02 上海天伟生物制药有限公司 A kind of compound and its production and use
KR20150027846A (en) 2010-03-15 2015-03-12 유나이티드 세러퓨틱스 코오포레이션 Treatment for pulmonary hypertension
CA2777070C (en) 2010-06-03 2019-11-05 United Therapeutics Corporation Treprostinil production
EP2582235A4 (en) 2010-06-15 2014-04-30 United Therapeutics Corp Oral treatment of digital ischemic lesions
WO2012006273A1 (en) 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
CA2710726C (en) 2010-07-22 2016-02-23 Alphora Research Inc. Synthesis of treprostinil and intermediates useful therein
CA2710725C (en) * 2010-07-22 2017-08-01 Alphora Research Inc. Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
JP5580491B2 (en) 2011-03-02 2014-08-27 ユナイテッド セラピューティクス コーポレイション Synthesis of intermediates for the production of treprostinil.
WO2013040068A2 (en) 2011-09-12 2013-03-21 Irix Pharmaceuticals, Inc. Process for preparing synthetic prostacyclins
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
WO2014159050A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
EP2970081A4 (en) 2013-03-15 2016-10-12 United Therapeutics Corp Salts of treprostinil
JP6594857B2 (en) 2013-04-30 2019-10-23 ユナイテッド セラピューティクス コーポレイション Controlled release formulation
US9593061B2 (en) * 2014-10-20 2017-03-14 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053517A2 (en) * 2001-01-05 2002-07-11 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
‘GFI (Guidance for Industry, Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, 56 pages, Published 08-2001) (Year: 2001) *
Berstein (3 pages, published 2012). (Year: 2012) *

Also Published As

Publication number Publication date
ES2778274T3 (en) 2020-08-10
WO2016064764A1 (en) 2016-04-28
CN107108427A (en) 2017-08-29
US20160107973A1 (en) 2016-04-21
US9593061B2 (en) 2017-03-14
EP3209415A1 (en) 2017-08-30
US20170158602A1 (en) 2017-06-08
JP6224872B1 (en) 2017-11-01
US20190233362A1 (en) 2019-08-01
CA2964804C (en) 2019-04-02
CA2964804A1 (en) 2016-04-28
US10196342B2 (en) 2019-02-05
US20250002442A1 (en) 2025-01-02
JP2017534615A (en) 2017-11-24
KR101890080B1 (en) 2018-09-20
US11225452B2 (en) 2022-01-18
US10774027B2 (en) 2020-09-15
KR20170113531A (en) 2017-10-12
US20200369592A1 (en) 2020-11-26
EP3209415B1 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
US11225452B2 (en) Synthesis of intermediates for producing prostacyclin derivatives
KR102405650B1 (en) Salts of treprostinil
TWI454453B (en) Intermediates for the synthesis of benzindene prostaglandins and preparations thereof
JP5535082B2 (en) Method for synthesizing bosentan, polymorphic forms thereof and salts thereof
KR20170081292A (en) An improved process to prepare treprostinil, the active ingredient in remodulin®
WO2016161956A1 (en) Preparation method of indacaterol or salt thereof
KR101063146B1 (en) Method for preparing pitavastatin intermediate and method for preparing pitavastatin hemicalcium salt
JP5745050B2 (en) Novel Montelukast 4-halobenzylamine salt and method for producing Montelukast sodium salt using the same
WO2023226456A1 (en) Method for preparing azoxystrobin and intermediate thereof
US10597410B2 (en) Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
US10807965B2 (en) Process for preparation of apalutamide
US20170297999A1 (en) Method for producing triphenylbutene derivative
JP2012506367A (en) Crystalline Montelukast salt
CN112521375A (en) Preparation method of rosuvastatin calcium intermediate
JP2023548916A (en) Method for producing biliverdin or its derivatives
WO2013038931A1 (en) Method of producing 2-oxo-2h-cyclohepta[b]furan analogue
JP2010533207A (en) Methods and intermediates for the production of tertiary alcohols as intermediates in the synthesis of montelukast
EP1948584A2 (en) Process for the preparation of cyclopentanone derivatives

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION